MX2018011939A - Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos. - Google Patents
Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.Info
- Publication number
- MX2018011939A MX2018011939A MX2018011939A MX2018011939A MX2018011939A MX 2018011939 A MX2018011939 A MX 2018011939A MX 2018011939 A MX2018011939 A MX 2018011939A MX 2018011939 A MX2018011939 A MX 2018011939A MX 2018011939 A MX2018011939 A MX 2018011939A
- Authority
- MX
- Mexico
- Prior art keywords
- glycosylated
- methods
- antibodies
- antibodies specific
- dual function
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Se proporcionan anticuerpos que se enlazan específicamente a la PD-L1 glicosilada con respecto a la PD-L1 no glicosilada, bloquean el enlace de PD-L1 a PD-1 y promueven la internalización y degradación de PD-L1. Se proporcionan anticuerpos que reconocen los epítopos específicos en la proteína PD-L1 glicosilada y que muestran las funciones dobles tanto del bloqueo como el enlace de PD-L1 a PD-1 y también facilitan la internalización de PDL1 en las células. En algunos aspectos, también se proporcionan polipéptidos PD-L1 que comprenden los residuos de aminoácidos glicosilados en las posiciones amino y carboxi terminal del dominio extracelular PD-L1. También se proporcionan métodos para utilizar tales anticuerpos para el tratamiento de cáncer, particularmente cáncer positivo a PD-L1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662314652P | 2016-03-29 | 2016-03-29 | |
US201662361312P | 2016-07-12 | 2016-07-12 | |
PCT/US2017/024027 WO2017172518A1 (en) | 2016-03-29 | 2017-03-24 | Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011939A true MX2018011939A (es) | 2019-05-20 |
Family
ID=58464701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011939A MX2018011939A (es) | 2016-03-29 | 2017-03-24 | Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11660352B2 (es) |
EP (2) | EP3943508B1 (es) |
JP (2) | JP7241541B2 (es) |
KR (2) | KR102418372B1 (es) |
CN (1) | CN109195991B (es) |
AU (1) | AU2017241440A1 (es) |
CA (1) | CA3017608A1 (es) |
ES (1) | ES2883297T3 (es) |
MX (1) | MX2018011939A (es) |
TW (2) | TWI764892B (es) |
WO (1) | WO2017172518A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3099704B1 (en) | 2014-01-27 | 2021-03-17 | Molecular Templates, Inc. | Mhc class i epitope delivering polypeptides |
US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
MX2018015584A (es) * | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
CA3043333A1 (en) | 2016-12-07 | 2018-06-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
WO2018140427A1 (en) | 2017-01-25 | 2018-08-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
JP7323200B2 (ja) | 2018-04-17 | 2023-08-08 | モレキュラー テンプレーツ,インク. | 脱免疫化志賀毒素aサブユニット足場を含むher2ターゲティング分子 |
CN112041348B (zh) | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
CN113795510A (zh) * | 2019-08-29 | 2021-12-14 | 荣昌生物制药(烟台)股份有限公司 | 抗pd-l1抗体及其应用 |
US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
MX2022003195A (es) | 2019-09-18 | 2022-04-11 | Molecular Templates Inc | Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga. |
EP4308242A1 (en) * | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
CN114842091B (zh) * | 2022-04-29 | 2023-05-23 | 广东工业大学 | 一种双目鸡蛋尺寸流水线测定方法 |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4606855A (en) | 1982-07-26 | 1986-08-19 | Mex Research Associates C/O Leon Reimer | Monoclonal antibody to digoxin |
US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3330160A1 (de) | 1983-08-20 | 1985-03-07 | Boehringer Ingelheim KG, 6507 Ingelheim | Monoklonaler antikoerper mit hoher affinitaet zum digoxin |
DE3342870A1 (de) | 1983-11-26 | 1985-06-05 | Boehringer Mannheim Gmbh, 6800 Mannheim | Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen |
US4767720A (en) | 1985-08-29 | 1988-08-30 | Hsc Research Development Corporation | Antidigoxin antibodies |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5164296A (en) | 1990-08-31 | 1992-11-17 | University Of Maryland At Baltimore | Assay methods involving ouabain |
US5656434A (en) | 1990-12-28 | 1997-08-12 | Suntory Limited | Monoclonal antibody against cardiac glycoside and utilization thereof |
DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
US5770376A (en) | 1992-12-02 | 1998-06-23 | Biomedical Sciences Research Laboratories, Inc. | Method of diagnosing and treating myocardial infarction and hypertension |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5420253A (en) | 1993-09-09 | 1995-05-30 | Willmar Poultry Company, Inc. | Method for purifying egg yolk immunoglobulins |
GB9325182D0 (en) | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
US6709873B1 (en) | 1997-04-09 | 2004-03-23 | Isodiagnostika Inc. | Method for production of antibodies to specific sites of rapamycin |
US6861572B1 (en) | 1997-11-14 | 2005-03-01 | Origen Therapeutics, Inc. | Production of proteins in eggs |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
US6432673B1 (en) | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
US6753407B2 (en) | 2000-08-15 | 2004-06-22 | North Carolina State University | Antimicrobial peptides isolated from fish |
US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
US6891024B2 (en) | 2001-05-24 | 2005-05-10 | The Curators Of The University Of Missouri | Monoclonal antibodies to Sarcocystis neurona and uses therefor |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
CN1777443B (zh) | 2002-07-19 | 2010-06-23 | 貝丝以色列女执事医疗中心 | 诊断和治疗先兆子痫或子痫的方法 |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
EP2481750A1 (en) | 2004-06-30 | 2012-08-01 | Mayo Foundation for Medical Education and Research | B7-DC binding antibody |
WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US9102717B2 (en) | 2010-03-01 | 2015-08-11 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
US9556281B2 (en) | 2011-08-15 | 2017-01-31 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
EP2903641A2 (en) | 2012-10-04 | 2015-08-12 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
EP3060581A4 (en) * | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
EP3083692B1 (en) | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
CN114380909A (zh) | 2015-03-30 | 2022-04-22 | 斯特库比股份有限公司 | 特异性针对糖基化的pd-l1的抗体及其使用方法 |
AU2016329251B2 (en) | 2015-10-02 | 2023-02-02 | F. Hoffmann-La Roche Ag | Anti-PD1 antibodies and methods of use |
JP2019518068A (ja) * | 2016-03-29 | 2019-06-27 | エスティーキューブ アンド カンパニー,インコーポレイテッド | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
-
2017
- 2017-03-24 EP EP21181598.0A patent/EP3943508B1/en active Active
- 2017-03-24 CN CN201780027832.4A patent/CN109195991B/zh active Active
- 2017-03-24 JP JP2018551425A patent/JP7241541B2/ja active Active
- 2017-03-24 ES ES17715372T patent/ES2883297T3/es active Active
- 2017-03-24 US US16/086,582 patent/US11660352B2/en active Active
- 2017-03-24 EP EP17715372.3A patent/EP3436481B1/en active Active
- 2017-03-24 WO PCT/US2017/024027 patent/WO2017172518A1/en active Application Filing
- 2017-03-24 KR KR1020227005650A patent/KR102418372B1/ko active IP Right Grant
- 2017-03-24 MX MX2018011939A patent/MX2018011939A/es unknown
- 2017-03-24 KR KR1020187031150A patent/KR102367074B1/ko active IP Right Grant
- 2017-03-24 CA CA3017608A patent/CA3017608A1/en active Pending
- 2017-03-24 AU AU2017241440A patent/AU2017241440A1/en active Pending
- 2017-03-28 TW TW106110393A patent/TWI764892B/zh active
- 2017-03-28 TW TW111114698A patent/TW202248217A/zh unknown
-
2022
- 2022-07-01 JP JP2022107042A patent/JP2022141715A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017241440A1 (en) | 2018-10-04 |
KR102418372B1 (ko) | 2022-07-08 |
JP2019513147A (ja) | 2019-05-23 |
CN109195991A (zh) | 2019-01-11 |
KR20220028156A (ko) | 2022-03-08 |
EP3943508B1 (en) | 2024-01-10 |
CN109195991B (zh) | 2023-10-31 |
US11660352B2 (en) | 2023-05-30 |
JP2022141715A (ja) | 2022-09-29 |
KR20180129872A (ko) | 2018-12-05 |
JP7241541B2 (ja) | 2023-03-17 |
EP3436481A1 (en) | 2019-02-06 |
CA3017608A1 (en) | 2017-10-05 |
WO2017172518A1 (en) | 2017-10-05 |
KR102367074B1 (ko) | 2022-02-25 |
TWI764892B (zh) | 2022-05-21 |
US20190083644A1 (en) | 2019-03-21 |
EP3943508A1 (en) | 2022-01-26 |
TW201739767A (zh) | 2017-11-16 |
EP3436481B1 (en) | 2021-06-30 |
TW202248217A (zh) | 2022-12-16 |
ES2883297T3 (es) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018011939A (es) | Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos. | |
MX2023001403A (es) | Neoantigenos y metodos de su uso. | |
AU2018256592A1 (en) | Binding proteins comprising at least two repeat domains against HER2 | |
MX2023007400A (es) | Moleculas de union a bcma y metodos de uso de las mismas. | |
PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
MX2018001787A (es) | Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas. | |
TN2018000044A1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
NZ756763A (en) | Engineered transferrin receptor binding polypeptides | |
WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
MX2022015847A (es) | Proteinas de union a cd123 y composiciones y metodos relacionados. | |
NZ629816A (en) | Therapeutic peptides | |
WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2016014647A (es) | Proteinas de fusion del ligando de ox40 (ox40l) y sus usos. | |
MY197562A (en) | Cd3 binding polypeptides | |
WO2018187356A3 (en) | Protein antigens and uses thereof | |
EA202090216A2 (ru) | Связывающие сывороточный альбумин домены фибронектина iii типа | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
MX365551B (es) | Proteinas de fusion de apelina y usos de estas. | |
PH12020500137A1 (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
WO2016149613A3 (en) | Selective mcl-1 binding peptides | |
MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
WO2018027039A8 (en) | COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION | |
WO2018069871A3 (en) | Anti-kras binding proteins |